Intravascular Large B-Cell Lymphoma (IVLBCL)

Intravascular Large B-Cell Lymphoma (IVLBCL) is an exceptionally rare subtype of diffuse large B-cell lymphoma (DLBCL) characterized by the selective proliferation of malignant large B lymphocytes within the lumens of small blood vessels — capillaries, venules, and sinusoids — without forming recognizable tumor masses. This unique pattern of spread means that standard lymphoma staging investigations, including PET-CT and lymph node examination, may appear normal even in the presence of widespread systemic disease.

IVLBCL was historically known as neoplastic angioendotheliomatosis and was once mistakenly classified as a vascular tumor. Recognition of its B-cell lymphoid origin has since led to its reclassification within the WHO lymphoma classification. The WHO 5th Edition (2022) retains IVLBCL as a distinct entity within large B-cell lymphomas.

The disease predominantly affects adults in the sixth and seventh decades of life. Its clinical presentation is notoriously heterogeneous, involving neurological dysfunction, skin lesions, unexplained fever, and multi-organ failure, often leading to significant diagnostic delay. Random skin biopsy and bone marrow trephine biopsy have emerged as critically important diagnostic tools that can identify intravascular tumor cells even in the absence of obvious cutaneous disease. Given the rarity and diagnostic challenge of IVLBCL, specialist hematopathology review and expert lymphoma center input are essential from the outset.

IVLBCL is classified by its predominant clinical presentation pattern. The WHO and published case series recognize three principal clinical variants that differ in their predominant sites of involvement, geographic distribution, and associated features. Understanding the variant guides diagnostic strategy and informs prognosis.

IVLBCL produces an exceptionally broad and variable symptom profile because malignant cells can obstruct vessels in virtually any organ. Symptoms reflect the specific organs involved. The absence of palpable lymphadenopathy or a visible tumor mass makes recognition challenging; many patients are investigated extensively before IVLBCL is considered.

The precise etiology of IVLBCL remains incompletely understood. The hallmark biological feature — selective retention of malignant B cells within vascular lumens — is thought to result from the loss of adhesion molecules, particularly CD29 (beta-1 integrin) and CD54 (ICAM-1), which are required for lymphocyte migration out of vessels. This aberrant adhesion molecule expression traps tumor cells within the vasculature rather than allowing extravasation into lymph node tissue.

Diagnosing IVLBCL is one of the most challenging problems in clinical hematology because conventional imaging studies — including PET-CT — may be normal or show only nonspecific findings. Diagnosis is established by identifying large atypical B lymphocytes within the lumens of small vessels on tissue biopsy. Random skin biopsy (even from normal-appearing skin) and bone marrow trephine biopsy are the most accessible routes to diagnosis and are recommended early in the workup when IVLBCL is suspected.

Conventional Ann Arbor staging has limited applicability in IVLBCL because disease is disseminated intravascularly without forming discrete tumor masses. In practice, risk stratification focuses on the presence of CNS involvement, the clinical variant, and performance status. The International Prognostic Index (IPI) for aggressive B-cell lymphomas is applied, though its predictive value in IVLBCL is less well-validated than in DLBCL.

R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is the established first-line standard of care for IVLBCL, producing response rates comparable to those seen in systemic DLBCL. The addition of rituximab has substantially improved outcomes. CNS prophylaxis is an important consideration given the high frequency of neurological involvement and the risk of CNS relapse. Treatment decisions should be made at specialist lymphoma centers with multidisciplinary input.

Growing molecular understanding of IVLBCL has opened several targeted therapy avenues. MYD88 and CD79B mutations implicate the B-cell receptor (BCR) and NF-kB signaling pathways, making BTK inhibitors a rational option. Novel antibody-drug conjugates and CAR-T cell therapies are being explored in relapsed large B-cell lymphomas, including uncommon subtypes such as IVLBCL.

Molecular characterization of IVLBCL at diagnosis is increasingly important for identifying targeted therapy eligibility and understanding disease biology. IVLBCL shares some molecular features with ABC-type DLBCL, including activating mutations in BCR/NF-kB pathway genes. Comprehensive profiling is recommended at diagnosis to guide treatment and clinical trial matching.

IVLBCL is one of the most diagnostically challenging lymphomas. Second opinions are frequently essential, not just valuable — the rarity of the disease, its diverse presentations, and the technical complexity of diagnosis mean that misdiagnosis and diagnostic delay are common. The following scenarios warrant specialist expert review.

IVLBCL carries a historically poor prognosis, largely attributable to delayed diagnosis and the aggressive nature of intravascular disease. However, outcomes have improved substantially in the rituximab era; patients who receive prompt R-CHOP-based treatment have substantially better outcomes than historically reported for pre-rituximab series. The cutaneous variant carries the most favorable prognosis among IVLBCL presentations.

Supportive care in IVLBCL is multidisciplinary and addresses the unique challenges of neurological sequelae, multi-organ involvement, and the toxicities of intensive immunochemotherapy. Coordinated care involving hematology, neurology, rehabilitation, and palliative medicine optimizes quality of life alongside active treatment.